Interview with the Innovators
Supported byAsk the Experts

Practical Strategies for Reduced Risk of Regorafenib-Related Side Effects

Tanios S. Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer,
Mayo Clinic Cancer Center Consultant
Mayo Clinic, Phoenix, AZ
Daniel Ahn, DO, MS
Assistant Professor of Medicine
Mayo Clinic, AZ
Dr. Bekaii-Saab and Dr. Ahn recommend clinical practice strategies that may help reduce Regorafenib-related side effects and improve patient quality of life.

Related Items

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: